Back to results
US 2020/0369725 A1Published application
Novel tumor-specific polypeptide and use thereof
AssigneeGenoimmune Therapeutics Co., Ltd.
InventorsYong HOU, Shuntao Luo, Ting An, Xiumei Lin, Bo Li, Guanglei Li
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel tumor-specific polypeptide and use thereof. In particular, the present invention relates to a tumor-specific polypeptide having high affinity for HLA-A0201 and having cytotoxic T lymphocyte inducing ability, and its use for diagnosing, preventing and treating diseases (especially cancer) associated with high expression of the TWISTNB gene or mutation(s) in the TWISTNB gene.
Claims14
A polypeptide or a derivative thereof selected from the group consisting of
- a) a polypeptide comprising or consisting of the amino acid sequence KLMGIVYKV as set forth in SEQ ID NO:
- 2;
- or
- b) a polypeptide having an amino acid sequence at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% identical to SEQ ID NO:
- 2, wherein said polypeptide has the ability of inducing cytotoxic T lymphocyte cells;
- or
- c) a polypeptide having an amino acid sequence comprising at least one or several amino acid substitutions, deletions and/or additions compared to SEQ ID NO:
- 2, wherein said polypeptide has the ability of inducing cytotoxic T lymphocyte cells;
- or
- d) a polypeptide derivative which is a derivative of any of a)-c), wherein the polypeptide derivative has the ability of inducing cytotoxic T lymphocyte cells.
7 more elements
3-4. (canceled)
6-37. (canceled)
46-53. (canceled)
Dependencies are inferred from the claim text.